prader willi glp 1 agonist Prader–Willi Syndrome in Adults: An Update On Nutritional Treatment and Pharmacological Approach | Current Obesity Reports Frontiers | Endocrine features of

Conflict of interest The authors declare no conflict of interest Authors contributions Conceptualization, formal analysis, original draft preparation (SKC), writingreview and editing (SKC, DC), supervision, project administration, and funding acquisition (SKC)

According to FDA labeling and clinical trials, HbA1c reductions of 1.01.5% are common in patients with type 2 diabetes, though the exact reduction varies by baseline A1c, dose, and individual response

Market Share Projections Novo Nordisk itself forecasts that oral weight-loss drugs will capture more than one-third of the total GLP-1 market by 2030

Dulaglutide and Kidney Function-Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis

By focusing more resources on research and development, pharmaceutical companies can develop more advanced incretin mimetic drugs with improved efficacy, safety, and novel delivery mechanisms